The Diversity of CYP2C19 Polymorphisms in the Thai Population: Implications for Precision Medicine
Issued Date
2024-01-01
Resource Type
eISSN
1178704X
Scopus ID
2-s2.0-85199765712
Journal Title
Application of Clinical Genetics
Volume
17
Start Page
95
End Page
105
Rights Holder(s)
SCOPUS
Bibliographic Citation
Application of Clinical Genetics Vol.17 (2024) , 95-105
Suggested Citation
Nakhonsri V., John S., Panumasmontol H., Jantorn M., Chanthot P., Hanpramukkun N., Meelarp S., Sukasem C., Tongsima S., Hasatsri S., Prawang A., Thaingtamtanha T., Vanwong N., Atasilp C., Chamnanphon M., Jinda P., Satapornpong P. The Diversity of CYP2C19 Polymorphisms in the Thai Population: Implications for Precision Medicine. Application of Clinical Genetics Vol.17 (2024) , 95-105. 105. doi:10.2147/TACG.S463965 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/100194
Title
The Diversity of CYP2C19 Polymorphisms in the Thai Population: Implications for Precision Medicine
Author's Affiliation
Ramathibodi Hospital
University of Ottawa
Chulalongkorn University
Universität Siegen
Rangsit University
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Thammasat University
Thailand National Center for Genetic Engineering and Biotechnology
Faculty of Medicine, Srinakharinwirot University
Ounjai Medical Clinic
University of Ottawa
Chulalongkorn University
Universität Siegen
Rangsit University
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Thammasat University
Thailand National Center for Genetic Engineering and Biotechnology
Faculty of Medicine, Srinakharinwirot University
Ounjai Medical Clinic
Corresponding Author(s)
Other Contributor(s)
Abstract
Introduction: CYP2C19 plays a major role in the metabolism of various drugs. The most common genetic variants were the CYP2C19*2 and *3 alleles (rs4244285 and rs4986893, non-functional variants). In previous studies, we found that genetic poly-morphisms in CYP2C19 variants influenced the active metabolites of clopidogrel and caused major adverse cardiovascular and cerebrovascular effects. However, the distribution of CYP2C19 varies among ethnic groups and according to adverse drug reactions. This study aimed to investigate the frequency of CYP2C19 genetic polymorphisms in the Thai population and analyze the differences in the frequency of CYP2C19 genetic polymorphisms between Thai and other populations. Methods: This study enrolled 211 unrelated healthy Thai individuals in total. We performed a real-time polymerase chain reaction to genotype CYP2C19*2 (681G > A) and CYP2C19*3 (636G > A). Results: In the Thai population, the CYP2C19*1 allele was the most prevalent at 70.14%, while the CYP2C19*2 and *3 alleles were found at frequencies of 25.36% and 4.50%, respectively. Conversely, the CYP2C19*3 allele was not detected in Caucasian, Hispanic, African, Italian, Macedonian, Tanzanian, or North Indian populations. The phenotypic profile of this gene revealed that the frequency of intermediate metabolizers (IMs) is nearly equal to that of extensive metabolizers (EMs), at 42.65% and 48.82% respectively, with genotypes *1/*2 (36.02%) and *1/*3 (6.63%). Likewise, poor metabolizers (PMs) with genotypes *2/*2 (6.16%), *2/*3 (2.37%), and *3/*3 (<1%) are more prevalent in our population as well. Conclusion: The distribution of CYP2C19 genotype and phenotype influenced by non-functional alleles has potential as a pharmacogenomics biomarker for precision medicine and is dependent on an ethnic-specific genetic variation database.